Siplizumab - CISMeF

Preferred Label : Siplizumab;

NCIt synonyms : Immunoglobulin G1, Anti-(human CD2 (Antigen))(Human-rat Monoclonal MEDI-507 G1-chain), Disulfide with Human-rat Monoclonal MEDI-507 Light Chain, Dimer;

NCIt related terms : MEDI-507;

NCIt definition : A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2 cells, selective suppression of the immune system, and control of activated T cell growth.;

Alternative definition : NCI-GLOSS: A monoclonal antibody that is being studied in the treatment of certain lymphoproliferative disorders and psoriasis.;

UNII : KUW1QG1ZM3;

CAS number : 288392-69-8;

Molecule name : MEDI-507;

Codes from synonyms : CDR0000367413; CDR0000367412;

Détails

Origin ID

C38685;

UMLS CUI

C1328709;

Currated CISMeF NLP mapping
- siplizumab [MeSH concept]
- siplizumab [MeSH Supplementary Concept]
False automatic mappings
- MEDI507 [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- siplizumab [MeSH concept]
- siplizumab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients